Posterior chamber collagen copolymer phakic intraocular lens with a central hole for moderate-to-high myopia

Cao, Xinfang; Wu, Weiliang; Wang, Yan; Xie, Chen; Tong, Jianping; Shen, Ye

doi:10.1097/md.0000000000004641

Cited by 19 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, we found the efficacy index to be 1.20, indicating that the mean postoperative UCVA was better than preoperative CDVA after implantation of Eyecryl Phakic IOL. Lisa et al [ 10 ] evaluated a posterior chamber pIOL with a similar design and a central hole implanted in 147 eyes and found an efficacy index of 1.04, whereas Shimizu et al [ 13 ] and Cao et al [ 7 ] found efficacy indices of 1.13 and 1.11, respectively, with the same lens model. In addition to the expected increase in UDVA, there was an improvement in CDVA of the patients.…”

Section: Discussionmentioning

confidence: 99%

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

Yaşa

Ürdem

Ağca

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To report clinical results of a foldable, hydrophilic acrylic, single-piece, injectable, posterior chamber phakic intraocular lens (pIOL). Material and Methods Medical records of patients who underwent posterior chamber phakic IOL (Eyecryl Phakic IOL, Biotech Vision Care, Ahmedabad, India) implantation for surgical correction of myopia were retrospectively reviewed. Only patients with at least a one-year follow-up were included. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell density (ECD), and pIOL vault were analyzed at 1, 3, 6, and 12 months after surgery. Complications observed during and after surgery were also recorded. Results The study included 58 eyes of 29 patients. Mean patient age was 32 ± 7 years. Spherical equivalent of manifest refraction was −13.41 ± 3.23 D preoperatively and −0.44 ± 0.55 D postoperatively. Preoperative CDVA was 0.29 ± 0.71 logMAR. Postoperative UDVA and CDVA were 0.21 ± 0.66 and 0.15 ± 0.69 logMAR, respectively, at the 12-month visit. At the 12-month visit, the efficacy index was 1.20 and the safety index was 1.39. Mean ECD was 2713 ± 339 cells/mm2 at the preoperative visit and 2608 ± 362 cells/mm2 at the 12-month visit (3.9% loss, p < 0.001). ECD loss from 3 months to 12 months was not statistically significant. No significant cataract formation, significant endothelial cell loss, glaucoma, uveitis, or any other vision-threatening complication was observed. Conclusion Based on postoperative experience, we have found that Eyecryl Phakic IOL is safe and effective for treating high myopia.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

Yaşa

Ürdem

Ağca

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Some discrepancies exist within the literature regarding endothelial cell loss secondary to ICL implantation. Gao et al [7] reported 2.0% endothelial cell loss at approximately 6 months postoperatively. Alfonso et al [24] reported 8.5% endothelial cell loss 6 months postoperatively.…”

Section: Discussionmentioning

confidence: 97%

“…The estimated number of people with myopia was 1406 million worldwide in 2000 and is predicted to reach about 4760 million by 2050 [5]. Posterior chamber phakic intraocular lens (PIOL) implantation has been reported to be a safe and effective surgical option for myopia correction [6][7][8][9][10]. Higher reversibility and less loss of best spectacle-corrected visual acuity have made this procedure more favorable than laser refractive surgery in patients with moderate to high myopia [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

A novel ophthalmic viscosurgical device-free phakic intraocular lens implantation makes myopic surgery safer

Pan

Wen

et al. 2020

Eye and Vis

View full text Add to dashboard Cite

Purpose: To assess the efficacy and safety of a novel ophthalmic viscosurgical device-free (OVD-free) method for posterior chamber phakic intraocular lens (PIOL) implantation in myopic eyes. Methods: In this retrospective cohort study, the medical records of myopic eyes that underwent PIOL (Implantable Collamer Lens, ICL) implantation for myopia correction at the Eye Hospital of Wenzhou Medical University between May 2015 and March 2017 were reviewed. A total of 49 eyes with complete data that met follow up requirements (2 h, 1 day, 1 week, 3 months postoperatively) were recruited. Based on the surgical techniques used, the eyes were divided into the OVD-free method group and the standard method group. The clinical data, including intraocular pressure (IOP), corrected distance visual acuity (CDVA) and spherical equivalent (SE), at each follow-up were collected for comparison. Endothelial cell loss and complications were also investigated. Results: Twenty-one eyes received the standard method, and 28 eyes received the OVD-free method. A rise in IOP > 22 mmHg at 2 h was noted in 14 eyes (66.7%) in the standard group and none (0%) in the OVD-free group (p < 0.001). The rise in IOP from baseline was significantly higher at 2 h in the standard group (10.5 ± 5.2 mmHg vs. 2.2 ± 3.3 mmHg, difference: 8.3, 95% CI 5.8 to 10.8; p < 0.001). There was a significant difference in the time course of LogMAR CDVA changes between the two groups (p = 0.047). The LogMAR CDVA was significantly better in the OVD-free method group compared to the standard group at 1 day (− 0.076, 95% CI − 0.134 to − 0.018; p = 0.012), 1 week (− 0.071, 95% CI − 0.135 to − 0.007; p = 0.03), but not at 3 months (− 0.046, 95% CI − 0.107 to 0.015; p = 0.134). There was no significant difference in the time course of SE changes between the two groups (p = 0.471; p = 0.705). In the OVD-free group, mean endothelial cell loss was 4.6% at 3 months (2522 ± 281 vs. 2407 ± 226 cells/ mm 2 , difference:-115, 95% CI − 295 to 65; p = 0.187). No complications were reported in both groups except for the early IOP elevation in the standard group during the observation period. Conclusions: The OVD-free method is safe and efficient for ICL implantation. It can be a safer method of ICL implantation compared to the standard method in that it completely eliminates ophthalmic viscoelastic devicesrelated complications without causing additional complications.

show abstract

“…One retrospective study of 63 eyes of Chinese showed that 97% were within ±0.5 D of target at 6 months after pIOL. [ 33 ] Although pIOL was shown to have a good safety and efficacy indices, there was risk of endothelial cell loss. [ 33 ]…”

Section: Discussionmentioning

confidence: 99%

Predictability and stability of laser-assisted subepithelial keratectomy with mitomycin C for the correction of high myopia

Fan

Chen

et al. 2017

Medicine

View full text Add to dashboard Cite

The purpose of this study was to evaluate the predictability and stability of laser-assisted subepithelial keratectomy (LASEK) with mitomycin C (MMC) in correction of high myopia (≤−6.0 diopters [D]) as compared to low-to-moderate myopia (>−6.0 D).This is a retrospective, comparative, cohort study which included 43 eyes of 43 consecutive patients who underwent LASEK with MMC in a private hospital in Hong Kong by a single surgeon. Twenty-five eyes had high myopia (mean spherical equivalent [SE] = −8.53 ± 1.82 D) and 18 eyes had low-to-moderate myopia (mean SE = −3.99 ± 1.37 D) before surgery.In terms of refractive predictability, mean SE was significantly better in eyes with preoperative low-to-moderate myopia than high myopia at 6 months (0.04 ± 0.23 vs 0.31 ± 0.52 D, P = .035). In terms of refractive stability, between 1 and 3 months, both groups had mean absolute change of SE of around 0.25 D. Between 3 and 6 months, preoperative low-to-moderate myopia group had significantly less absolute change of SE compared to high myopia group (0.07 vs 0.23 D, P = .003). More eyes with preoperative high myopia changed SE by more than 0.25 D than those with low-to-moderate myopia between 3 and 6 months (32.0% vs 5.6%, P = .057).In conclusion, LASEK with MMC is more unpredictable and unstable in correction of high myopia than low-to-moderate myopia. The refractive outcome of most low-to-moderate myopia correction stabilizes at 3 months. Stability is not achieved until after 6 months in high myopia correction.

show abstract

Posterior chamber collagen copolymer phakic intraocular lens with a central hole for moderate-to-high myopia

Cited by 19 publications

References 35 publications

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

A novel ophthalmic viscosurgical device-free phakic intraocular lens implantation makes myopic surgery safer

Predictability and stability of laser-assisted subepithelial keratectomy with mitomycin C for the correction of high myopia

Contact Info

Product

Resources

About